Table 2 Information of post-BCS patients’ characteristics
Variables | Post-BCS patients after 1:1 PS match | p value | ||
|---|---|---|---|---|
RT N = 6582 (%) |  | No RT N = 6582 (%) | ||
Age group (years) | Â | Â | 0.96 | |
 20–46 | 1578 (23.97) | 1594 (24.22) |  | |
 47–52 | 1490 (22.64) | 1468 (22.30) |  | |
 53–60 | 1534 (23.31) | 1542 (23.43) |  | |
  > 60 | 1980 (30.08) | 1978 (30.05) |  | |
Subtype | Â | Â | 0.74 | |
 Luminal A | 2646 (40.20) | 2607 (39.61) |  | |
 Luminal B/HER2 - | 373 (5.67) | 396 (6.02) |  | |
 Luminal B/HER2+ | 667 (10.13) | 705 (10.71) |  | |
 Basal-like | 390 (5.93) | 398 (6.05) |  | |
 HER2-enriched | 382.00 (5.80) | 394 (5.99) |  | |
 Unknown | 2124 (32.27) | 2082 (31.63) |  | |
RT dose (cGy) |  |  |  < 0.0001 | |
 0 | – | 6582 (100) |  | |
 3000–5040 | 711 (10.80) | – |  | |
 5040–6040 | 4037 (61.33) | – |  | |
  > 6040 | 1834 (27.86) | – |  | |
C-stage | Â | Â | 0.42 | |
 0 | 423 (6.43) | 445 (6.76) |  | |
 I | 3231 (49.09) | 3173 (48.21) |  | |
 II | 2607 (39.61) | 2627 (39.91) |  | |
 III | 208 (3.61) | 237 (3.60) |  | |
 IV | 113 (1.72) | 100 (1.52) |  | |
P-stage | Â | Â | 0.21 | |
 0 | 184 (2.80) | 194 (2.95) |  | |
 I | 3412 (51.84) | 3307 (50.24) |  | |
 II | 2300 (34.94) | 2330 (35.40) |  | |
 III | 310 (4.71) | 364 (5.53) |  | |
 IV | 108 (1.64) | 102 (1.55) |  | |
 Unknown | 268 (4.07) | 285 (4.33) |  | |
Comorbidities | Â | Â | Â | |
 COPD | 263 (4.00) | 292 (4.44) | 0.20 | |
 Hypertension | 1565 (23.78) | 1537 (23.35) | 0.56 | |
 Diabetes mellitus | 667 (10.13) | 710 (10.79) | 0.22 | |
 CKD | 132 (2.01) | 153 (2.32) | 0.20 | |
 Heart failure | 40 (0.61) | 46 (0.70) | 0.51 | |
 Liver disease | 326 (4.95) | 371 (5.64) | 0.07 | |
 Liver cirrhosis | 24 (0.36) | 23 (0.35) | 0.88 | |
Chemotherapy | 3083 (46.84) | 3101 (47.11) | 0.75 | |
Hormone therapy | 5016 (76.21) | 4959 (75.34) | 0.24 | |
Target therapy | 345 (5.24) | 400 (6.08) | 0.03 | |
Anti-cancer agents | Â | Â | Â | |
 Doxorubicin | 616 (9.36) | 464 (7.05) |  < 0.0001 | |
 Epirubicin | 1797 (27.30) | 1709 (25.96) | 0.08 | |
 Docetaxel | 1297 (19.71) | 1037 (15.76) |  < 0.001 | |
 Paclitaxel | 189 (2.87) | 206 (3.13) | 0.38 | |
 Carboplatin | 15 (0.23) | 22 (0.33) | 0.24 | |
 Cyclophosphamide | 2895 (43.98) | 2827 (42.95) | 0.23 | |
 Fluorouracil | 1795 (27.27) | 1804 (27.41) | 0.86 | |
 Methotrexate | 218 (3.31) | 283 (4.30) | 0.003 | |
Family income (NTD per month) | Â | Â | 0.95 | |
  < 20,100 | 1636 (24.86) | 1653 (25.11) |  | |
 20,101–22,800 | 1138 (17.29) | 1148 (17.44) |  | |
 22,801–42000 | 2007 (30.49) | 1978 (30.05) |  | |
  > 42,000 | 1801 (27.36) | 1803 (27.39) |  | |
Urbanization level | Â | Â | 0.70 | |
 City | 1817 (27.61) | 1776 (26.98) |  | |
 Satellite cities | 3462 (52.60) | 3482 (52.90) |  | |
 Rural areas | 1303 (19.80) | 1324 (20.12) |  | |
Geographic region | Â | Â | 0.06 | |
 North | 3016 (45.82) | 3064 (46.55) |  | |
 Central | 1637 (24.87) | 1630 (24.76) |  | |
 South | 1839 (27.94) | 1764 (26.80) |  | |
 East | 90 (1.37) | 124 (1.88) |  | |